Hepatitis C recurrence is not adversely affected by the use of donation after cardiac death liver allografts

Liver Transplantation

Volumn 16, Issue 11, 2010, Pages 1288-1295

  Tao, Ran ^a   Ruppert, Kristine ^a   Cruz Jr , Ruy J ^a   Malik, Shahid M ^a   Shaikh, Obaid ^a   Ahmad, Jawad ^a   Dimartini, Andrea ^a   Humar, Abhinav ^a   Fontes, Paulo A ^a   De Vera, Michael E ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ALPHA2B INTERFERON; ASPARTATE AMINOTRANSFERASE; CYCLOSPORIN; GANCICLOVIR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RAPAMYCIN; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ADULT; ALLOGRAFT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN DEATH; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT SURVIVAL; HEART DEATH; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER FIBROSIS; LIVER FUNCTION; LIVER GRAFT; LIVER GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; ORGAN DONOR; PRIORITY JOURNAL; RECURRENT DISEASE; SURVIVAL RATE; TREATMENT OUTCOME;

BIOPSY; BRAIN DEATH; CASE-CONTROL STUDIES; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSION; LIVER; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECURRENCE; RISK FACTORS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 78349254673     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22168     Document Type: Article

References (34)

1. Wiesner RH, Sorrell M, Villamil F,. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9: S1 - S9.
2. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823 - 830.
3. Berenguer M, Crippin J, Gish R, Bass N, Bostrom A, Netto G, et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003; 38: 34 - 41.
4. Selzner N, Girgrah N, Lilly L, Guindi M, Selzner M, Therapondos G, et al. The difference in fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age. Liver Transpl 2008; 14: 1778 - 1786.
5. Rayhill SC, Wu YM, Katz DA, Voigt MD, Labrecque DR, Kirby PA, et al. Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C. Transplantation 2007; 84: 331 - 339.
6. Baron PW, Sindram D, Higdon D, Howell DN, Gottfried MR, Tuttle-Newhall JE, Clavien PA,. Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation. Liver Transpl 2000; 6: 407 - 412.
7. Watt K, Lyden E, Gulizia JM, McCashland TM,. Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome. Liver Transpl 2005; 12: 134 - 139.
8. Charlton M, Seaberg E,. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl 1999; 5: S107 - S114.
9. Belli LS, Burroughs AK, Burra P, Alberti AB, Samonakis D, Camma C, et al. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl 2007; 13: 733 - 740.
10. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673 - 684.
11. Marcos A, Eghtesad B, Fung JJ, Fontes P, Patel K, Devera M, et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation 2004; 78: 966 - 971.
12. Eghtesad B, Fung JJ, Demetris AJ, Murase N, Ness R, Bass DC, et al. Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles. Liver Transpl 2005; 11: 1343 - 1352.
13. Roche B, Didier S,. Steroid use in HCV-infected liver transplant recipients. Nat Rev Gastroenterol Hepatol 2009; 6: 198 - 200.
14. Burak KW, Kremers WK, Batts KP, Wiesner RH, Rosen CB, Razonable RR, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002; 8: 362 - 369.
15. de Vera ME, Dvorchik I, Tom K, Eghtesad B, Thai N, Shakil O, et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant 2006; 6: 2983 - 2893.
16. Mateo, Cho Y, Singh G, Stapfer M, Donovan J, Kahn J, et al. Risk factors for graft survival after liver transplantation from donation after cardiac death donors: an analysis of OPTN/UNOS data. Am J Transplant 2006; 6: 791 - 796.
17. de Vera ME, Lopez-Solis R, Dvorchik I, Campos S, Morris W, Demetris AJ, et al. Liver transplantation using donation after cardiac death donors: long-term follow-up from a single center. Am J Transplant 2009; 9: 773 - 781.
18. Foley DP, Fernandez LA, Leverson G, Chin LT, Krieger N, Cooper JT, et al. Donation after cardiac death: the University of Wisconsin experience with liver transplantation. Ann Surg 2005; 242: 724 - 731.
19. Chan EY, Olson LC, Kisthard JA, Perkins JD, Bakthavatsalam R, Halldorson JB, et al. Ischemic cholangiopathy following liver transplantation from donation after cardiac death donors. Liver Transpl 2008; 14: 604 - 610.
20. Grewal HP, Willingham DL, Nguyen J, Hewitt WR, Taner BC, Cornell D, et al. Liver transplantation using controlled donation after cardiac death donors: an analysis of a large single-center experience. Liver Transpl 2009; 15: 1072 - 1082.
21. Yamamoto S, Wilczek HE, Duraj FF, Groth CG, Ericzon BG,. Liver transplantation with grafts from controlled donors after cardiac death: a 20-year follow-up at a single center. Am J Transplant 2010; 10: 602 - 611.
22. Katz LH, Mor E, Brown M, Bar-Nathan N, Shaharabani E, Sulkes J, et al. Recurrent hepatitis C virus disease after liver transplantation and concurrent biliary tract complications: poor outcome. Clin Transplant 2006; 20: 465 - 470.
23. DiMartini A, Fontes P, Dew MA, Lotrich FE, de Vera ME,. Age, Model for End-Stage Liver Disease score, and organ functioning predict posttransplant tacrolimus neurotoxicity. Liver Transpl 2008; 14: 815 - 822.
24. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696 - 699.
25. Brown H, Prescott R,. Applied Mixed Models in Medicine. 2nd ed. West Sussex, England: John Wiley & Sons; 2006.
26. Yagci G, Fernandez LA, Knechtle SJ, D'Alessandro AM, Chin LT, Musat AI, et al. The impact of donor variables on the outcome of orthotopic liver transplantation for hepatitis C. Transplant Proc 2008; 40: 219 - 223.
27. Katz E, Mor E, Schwartz ME, Theise N, Patel T, Miller CM,. Preservation injury in clinical liver transplantation: incidence and effect on rejection and survival. Clin Transplant 1994; 8: 492 - 496.
28. Busquets J, Figueras J, Serrano T, Torras J, Ramos E, Rafecas A, et al. Postreperfusion biopsies are useful in predicting complications after liver transplantation. Liver Transpl 2001; 7: 432 - 435.
29. Berenguer M,. Risk of extended criteria donors in hepatitis C virus-positive recipients. Liver Transpl 2008; 14: S45 - S50.
30. Berenguer M, Aguilera V, Prieto M, San Juan F, Rayon JM, Benlloch S, et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 2006; 44: 717 - 722.
31. Prieto M, Berenguer M, Rayon JM, Cordoba J, Arguello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following liver transplantation: relationship with rejection episodes. Hepatology 1999; 29: 250 - 256.
32. Lake JR,. Immunosuppression and outcomes of patients transplanted for hepatitis C. J Hepatol 2006; 44: 627 - 629.
33. Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41: 830 - 836.
34. Humar A, Kumar D, Raboud J, Caliendo AM, Moussa G, Levy G, et al. Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation. Am J Transplant 2002; 2: 461 - 466.